Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.

Antimicrobial Agents and Chemotherapy
C JuanSpanish Network for Research in Infectious Diseases

Abstract

The activity of the new cephalosporin CXA-101 (CXA), previously designated FR264205, was evaluated against a collection of 236 carbapenem-resistant P. aeruginosa isolates, including 165 different clonal types, from a Spanish multicenter (127-hospital) study. The MICs of CXA were compared to the susceptibility results for antipseudomonal penicillins, cephalosporins, carbapenems, aminoglycosides, and fluoroquinolones. The MIC of CXA in combination with tazobactam (4 and 8 microg/ml) was determined for strains with high CXA MICs. The presence of acquired beta-lactamases was investigated by isoelectric focusing and PCR amplification followed by sequencing. Additional beta-lactamase genes were identified by cloning and sequencing. The CXA MIC50/MIC90 for the complete collection of carbapenem-resistant P. aeruginosa isolates was 1/4 microg/ml, with 95.3% of the isolates showing an MIC of <or=8 microg/ml. Cross-resistance with any of the antibiotics tested was not observed; the MIC50/MIC90 of CXA-101 was still 1/4 when multidrug-resistant (MDR) strains (42% of all tested isolates) or AmpC-hyperproducing clones (53%) were analyzed. Almost all (10/11) of the strains showing a CXA MIC of >8 microg/ml produced a horizontally acquired beta...Continue Reading

References

Dec 25, 1989·Nucleic Acids Research·A W Smith, B H Iglewski
Dec 10, 1998·Journal of Internal Medicine·L LeiboviciS D Pitlik
Nov 18, 2000·Antimicrobial Agents and Chemotherapy·N MasudaT Nishino
Feb 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David M Livermore
Nov 19, 2002·Antimicrobial Agents and Chemotherapy·Antonio OliverFred C Tenover
Jan 22, 2003·Environmental Microbiology·Jean-Paul PirnayMartin Zizi
Jan 7, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·K Poole
Mar 8, 2005·Journal of Clinical Microbiology·A DeplanoM J Struelens
Apr 16, 2005·Clinical Microbiology Reviews·Timothy R WalshPatrice Nordmann
Apr 28, 2005·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Sep 8, 2006·Enfermedades infecciosas y microbiología clínica·Marta TatoRafael Cantón
Dec 6, 2006·Antimicrobial Agents and Chemotherapy·Shinobu TakedaKazuo Hatano
Feb 3, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N MesarosF Van Bambeke
Apr 7, 2007·The Journal of Antimicrobial Chemotherapy·J D CavalloUNKNOWN GERPA (Groupe d'Etude de la Résistance de Pseudomonas aeruginosa aux antibiotiques)
Jul 24, 2007·International Journal of Antimicrobial Agents·Shinobu TakedaKeizo Yamaguchi
Jul 27, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C PeñaJ Ariza
Aug 8, 2007·Antimicrobial Agents and Chemotherapy·Didier HocquetPatrick Plésiat
Sep 24, 2008·Antimicrobial Agents and Chemotherapy·Gian Maria RossoliniLaura Pagani
May 12, 2009·International Journal of Antimicrobial Agents·David M LivermoreMarina Warner

❮ Previous
Next ❯

Citations

Jun 13, 2012·The Journal of Antimicrobial Chemotherapy·Peter C Appelbaum
Jun 16, 2010·Antimicrobial Agents and Chemotherapy·Bartolomé MoyáAntonio Oliver
Apr 1, 2011·Journal of Clinical Microbiology·Didier HocquetPatrick Plésiat
Oct 9, 2013·Current Infectious Disease Reports·Gopi PatelShirish Huprikar
Aug 21, 2014·Expert Review of Anti-infective Therapy·Emilio MasedaFernando Gilsanz
Dec 8, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G MikucionyteA Oliver
Feb 24, 2012·Journal of Basic Microbiology·Khadar Syed MusthafaArumugam Veera Ravi
Jan 26, 2013·Annals of the New York Academy of Sciences·George H Talbot
Apr 11, 2015·International Journal of Antimicrobial Agents·Anaïs PotronPatrice Nordmann
Oct 24, 2014·Future Microbiology·Garyphallia PoulakouGeorge Dimopoulos
Nov 13, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Qq WanH Yuan
Jun 22, 2016·Expert Opinion on Drug Metabolism & Toxicology·Florian M Wagenlehner, Jakhongir F Alidjanov
Oct 27, 2015·Pharmacotherapy·Keith S Kaye, Jason M Pogue
Mar 24, 2016·Angewandte Chemie·Mathieu F ChellatRainer Riedl
Nov 23, 2016·Journal of Basic Microbiology·Syed Ghazanfar AliSwaranjit Singh Cameotra
Nov 9, 2016·Antimicrobial Agents and Chemotherapy·Deanna J BuehrleM Hong Nguyen
Sep 7, 2017·Antimicrobial Agents and Chemotherapy·Ester Del Barrio-TofiñoAntonio Oliver
Dec 8, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·David CluckJonathan Moorman
Dec 19, 2019·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Snehal PalweArun S Kharat
Aug 12, 2015·Current Opinion in Critical Care·Matteo Bassetti, Elda Righi
Nov 4, 2017·In Silico Pharmacology·Syed Ghazanfar AliAbbas Ali Mahdi
Apr 23, 2019·Expert Review of Anti-infective Therapy·Georgios L VoulgarisMatthew E Falagas
Jan 1, 2014·Antibiotics·Wenling QinStefano Biondi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.